SCHEMBL5216715

SCHEMBL5216715

c1ccc(Oc2cccc(-n3cc(-c4cnc5ccccc5n4)cn3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MKNK1 Q9BUB5 5/20 0.47
HTT P42858 2/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 2/20 0.43
GRM5 P41594 1/20 0.43
GRM4 Q14833 4/20 0.41
KCNH2 Q12809 2/20 0.41
HTR2B P41595 1/20 0.41
MTNR1A P48039 1/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.40
ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216414 0.90 ALDH1A1 (0.47) ALDH1A1HPGDNPSR1HTTNPC1
SCHEMBL5216692 0.88 MKNK1 (0.57) ALDH1A1MKNK1NPC1RAB9AGRM4
SCHEMBL5218314 0.86 GRM4 (0.54) MKNK1HTTNPC1RAB9AGRM5
SCHEMBL5216495 0.86 GRM4 (0.54) NPC1RAB9AGRM4KCNH2HTR2B
SCHEMBL5216682 0.85 FGFR1 (0.49) MKNK1HTTNPC1RAB9AGRM5
SCHEMBL5217224 0.82 MKNK1 (0.52) ALDH1A1MKNK1HTTNPC1RAB9A
SCHEMBL5217700 0.82 NPC1 (0.45) MKNK1NPC1RAB9AGRM5GRM4
SCHEMBL8353703 0.82 BCHE (0.51) ALDH1A1NPC1RAB9AGRM5GRM4
SCHEMBL182208 0.81 KMT2A (0.55) NPSR1NPC1RAB9AGRM5MAPT
SCHEMBL5216133 0.80 GRM5 (0.42) MKNK1NPC1RAB9AGRM5GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C ALDH1A1 2988/4885HPGD 2305/4885NPSR1 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.